monoclonal antibodies Archives
Vanderbilt’s Crowe receives the Building the Foundation Award from Research!America
Oct. 6, 2022—Vanderbilt's James Crowe Jr., MD, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization.
COVID antibody research conducted at VUMC lands national award
Aug. 24, 2022—A long-acting antibody combination discovered at Vanderbilt University Medical Center that protects against COVID-19 in high-risk individuals has received a gold medal in the 2022 R&D 100 awards program announced Aug. 22 by R&D World Magazine.
Technique hastens COVID-19 antibody discovery
Mar. 10, 2022—Optimization of a technique developed at Vanderbilt University Medical Center enables rapid and efficient identification of neutralizing monoclonal antibodies against the virus that causes COVID-19.
COVID-19: two years of challenges, lessons, victories
Mar. 3, 2022—Two years ago this week, the cataclysmic coronavirus known as SARS-CoV-2 arrived in Middle Tennessee.
Pandemic leads to broader use of monoclonal antibodies
Feb. 17, 2022—Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.
Omicron evades some but not all monoclonal antibodies: study
Jan. 20, 2022—A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.
Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization
Dec. 9, 2021—The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which protects against COVID-19, discovered last year at Vanderbilt University Medical Center.
Long-acting antibody combo developed at VUMC reduces COVID-19 risk and symptoms
Dec. 2, 2021— by Bill Snyder The global biopharmaceutical company AstraZeneca announced more good news about its long-acting combination of two monoclonal antibodies against COVID-19 that were discovered at Vanderbilt University Medical Center. In a prevention trial, one prophylactic, intramuscular injection of the antibody combination, called AZD7442, reduced the risk of symptoms occurring after exposure to the...
Zost honored for research on COVID-19, other life-threatening viral diseases
Oct. 28, 2021—Vanderbilt's Seth Zost, PhD, has been awarded a major international prize for his research on COVID-19 and other life-threatening viral diseases.
“Ultra-potent” antibody against COVID-19 variants isolated at VUMC
Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.
VUMC antibodies help neutralize two deadly viruses: study
Sep. 8, 2021—Vanderbilt researchers have isolated monoclonal antibodies that prevent severe illness and death caused by two emerging and deadly viruses called Nipah and Hendra.
COVID-19 antibody ‘cocktail’ discovered at VUMC protects chronically ill: study
Aug. 20, 2021—A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.
